What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Cardiology
David D. Waters mostly deals with Internal medicine, Cardiology, Myocardial infarction, Surgery and Cholesterol.
His Internal medicine research incorporates elements of Diabetes mellitus and Endocrinology.
His Cardiology study frequently draws connections between related disciplines such as Risk factor.
He has researched Myocardial infarction in several fields, including Framingham Risk Score, Heart failure, Gastroenterology, CETP inhibitor and Evacetrapib.
His study in Surgery is interdisciplinary in nature, drawing from both Menopause, Placebo and Acquired immunodeficiency syndrome.
As part of one scientific family, David D. Waters deals mainly with the area of Cholesterol, narrowing it down to issues related to the Vascular disease, and often Circulatory system, Artery, Blood vessel, Intima-media thickness and Blood lipids.
His most cited work include:
- Intensive lipid lowering with atorvastatin in patients with stable coronary disease. (2894 citations)
- Effects of Torcetrapib in Patients at High Risk for Coronary Events (2489 citations)
- Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. (2093 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Cardiology, Myocardial infarction, Atorvastatin and Statin.
His study looks at the relationship between Internal medicine and topics such as Surgery, which overlap with Placebo.
His work carried out in the field of Cardiology brings together such families of science as Stroke and Clinical trial.
His study explores the link between Myocardial infarction and topics such as Heart failure that cross with problems in Intensive care medicine.
His Atorvastatin research incorporates elements of MIRACL, Clinical endpoint, Randomized controlled trial and Hazard ratio.
The Statin study combines topics in areas such as Gastroenterology and Disease.
He most often published in these fields:
- Internal medicine (80.53%)
- Cardiology (59.41%)
- Myocardial infarction (26.40%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (80.53%)
- Cardiology clinic (4.95%)
- Statin (17.82%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Cardiology clinic, Statin, Cardiology and MEDLINE.
In the field of Internal medicine, his study on Atorvastatin and Myocardial infarction overlaps with subjects such as In patient and PCSK9.
His research in Myocardial infarction intersects with topics in Stroke, Randomized controlled trial, Surgery and Heart failure.
His Statin research focuses on Adverse effect and how it relates to Confidence interval, Relative risk and Meta-analysis.
His research on Cardiology frequently links to adjacent areas such as Pulse pressure.
His MEDLINE research includes elements of Incidence, Colchicine, Intensive care medicine, Tuberculosis and Risk factor.
Between 2014 and 2021, his most popular works were:
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction (477 citations)
- HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. (405 citations)
- THE EFFECT OF STATIN THERAPY ON HEART FAILURE EVENTS: A COLLABORATIVE META-ANALYSIS OF UNPUBLISHED DATA FROM MAJOR RANDOMIZED TRIALS (72 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Disease
David D. Waters mainly focuses on Internal medicine, Statin, Intensive care medicine, Atorvastatin and Myocardial infarction.
His research integrates issues of Endocrinology, Type 2 diabetes and Cardiology in his study of Internal medicine.
The Cardiology study which covers Hazard ratio that intersects with Coronary artery disease.
His Statin research is multidisciplinary, relying on both Placebo, Cholesterol, Adverse effect and Evolocumab.
In his study, Lovastatin, Hypertriglyceridemia, Simvastatin, Kidney disease and Hemodialysis is strongly linked to Rosuvastatin, which falls under the umbrella field of Atorvastatin.
His biological study spans a wide range of topics, including Stroke and Surgery.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
